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Sumnlfl~ 
Cytokines  belonging  to  the  RANTES/SIS  family  are  highly  induced  in  a  number  of 
pathophysiological processes such as autoimmune disorders, cancers, atherosderosis, and chronic 
inflammation.  However,  apart  from their chemotactic activity on monocytes and particular 
lymphocyte types, the biological activities in the human system of this recently discovered cytokine 
family are largely unknown. Here we report that one family member, described as monocyte 
chemotactic protein  1  (MCP-1),  strongly  activates  mature  human basophils  in  a  pertussis 
toxin-sensitive manner. MCP-1 causes a rise in the cytosolic free calcium level in basophils and 
monocytes, but not in other blood leukocyte types, and triggers basophil degranulation at low 
concentrations (ED50  =  3-10  riM).  Thus,  MCP-1 is a cytokine capable of directly inducing 
histamine release by basophils.  Furthermore, MCP-1 promotes the formation of leukotriene C4 
by basophils pretreated with interleukin 3 (IL-3), Ib 5, or granulocyte/macrophage  colony-stimulating 
factor. MCP-l-induced basophil mediator release may play an important role in allergic inflammation 
and other pathologies expressing MCP-1. 
I 
n contrast to other human cytokines, the members of the 
bipartite platelet factor 4 superfamily seem to exert a rather 
restricted profile of biological  activities.  Members of the 
"C-X-C branch" (according to the position of the first two 
cysteines in the conserved motif), also known as neutrophil- 
activating peptide (NAP)I/II-,8 family, exert proinflamma- 
tory activity mainly through their action on neutrophils (e.g., 
IL-8 and NAP-2), whereas members of the "C-C branch," 
termed  R.ANTES/SIS  family,  appear  to  attract  certain 
mononuclear cells (1-3). RANTES, the macrophage inflam- 
matory protein lot (MIP-lc  0  and MIP-lfl are chemotactic 
for distinct lymphocyte populations (3, 4), while MCP-1 has 
been described as a specific monocyte chemoattractant (3, 5-7). 
Basophils,  rare leukocyte types in peripheral blood, are an 
important source of vasoactive and inflammatory mediators 
(8), but their participation in disease is largely unknown. They 
are triggered to release histamine and leukotriene C4 (LTC4) 
by IgE receptor crosslinking, by chemotactic peptides, i.e., 
FMLP or C5a, and by ceU-derived histamine-releasing factors 
(9-13). Although certain cytokines, such as the hematopoi- 
etic growth factors IL3, IL-5, GM-CSF, as well as IL-8, can 
affect basophil mediator release (9-11), none of the known 
cytokines examined so far consistently induce basophil de- 
granulation by themselves. At least part of the cell-derived 
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histamine-releasing  activity (HRA) can be attributed to a frac- 
tion of small molecular mass (8-12 kD) cationic peptide(s) 
(12,  13).  In the course of our studies on histamine release 
induced by cytokines of the platelet factor 4 family, we found 
that none of the members of the C-X-C branch could ac- 
count for the HRA of the cationic peptide fraction. In fact, 
even the most active peptide, IL-8, up to a 100-nM concen- 
tration, induces histamine release only in basophils primed 
with IL-3, GM-CSF, or IL-5 (11). The present study suggests 
that MCP-1 can account for at least part of the HRA from 
stimulated mononuclear cells. 
Materials and Methods 
Reagents.  Dextran  and Ficoll-Hypaque were obtained from 
Pharmacia Fine Chemicals (Uppsala, Sweden); Hepes was from 
Calbiochem-Behring Corp. (La Jolla, CA); BSA, fatty acid free, 
was from Boehringer Mannheim, Inc. (Mannheim, FRG); EDTA 
was from Fluka AG (Buchs, Switzerland); and Dynabeads M-450 
Pan T and Pan B were from Dynal A.S. (Skoyen, Norway). Per- 
tussis toxin (PT) and its B subunit were from List Biological  Labora- 
tories Inc. (Campbell, CA). 
CellStimuli.  Recombinant human (rh)MCP-1 (76 amino adds, 
8.5 kD; reference 7), expressed in Escherichia coli and purified to 
99% as assessed by SDS-PAGE and HPLC, was from PreproTech 
Inc. (Rocky Hill, NJ). rhlL-3 and rhlL-8 were obtained from Sandoz 
Ltd. (Basel, Switzerland; and Vienna, Austria). The anaphylatoxins 
were purified from yeast-activated human serum as described (10, 
14). The purified mAb 29C6 directed against the high affinity IgE 
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Roche (Nutley, NJ). 
Cell Preparation.  PBMC containing 1-6% basophils  were iso- 
lated from venous blood of unselected human volunteers by Ficoll- 
Hypaque density centrifugation exactly as described previously (9, 
10). For measurement of intracellular calcium levels, basophils, 
monocytes, and neutrophils were purified from the same leukocyte 
preparation by discontinuous Percoll gradient centrifugation and 
negative selection of basophils  with immunomagnetic beads  as 
reported previously (9; 14a). Basophils, purified to 80-91%, were 
contaminated with neutrophils (1-16%), lymphocytes (2-12%), 
and monocytes (0-3%). Monocytes were purified to ,~90% (10% 
lymphocytes); neutrophil purity was >99%, as assessed by stained 
cytocentrifuge slides. 
Mediator Release Assay.  Cells were suspended in HACM buffer 
(20 mM Hepes,  125 mM NaC1, 5 mM KC1, 1 mM CaC12, 1 mM 
MgCI2,  0.5  mM glucose,  and  0.025%  BSA),  and experiments 
were performed in a shaking water bath at 37~  as described  (9, 
10). The reaction was stopped by placing the tubes in ice-cold water. 
Histamine and LTC4 release were measured in the cell superna- 
rants as described (9,  10). 
Measurement  of Cytosolic Free Calcium ([Ca2+]i).  After loading 
the cells with 0.3  nmol fura-2/AM per  106 cells for 30 rain at 
37~  and washing in HACM buffer,  fluorescence  of the stirred 
thermostated cell suspension was monitored continuously, and the 
percent fura-2 saturation was calculated as described (15). Resting 
[Ca2+]i corresponded to 50  _+ 2% fura-2 saturation. In some ex- 
periments, basophils  were preincubated for 90 min at 37~  with 
or without PT or its B subunit before starting the mediator release 
experiments of [Ca2+]i measurements. 
Results  and  Discussion 
Fig.  1 A  shows that rhMCP-1 directly induces histamine 
release by basophils  in  a  concentration-dependent  manner 
within a range of 3-100 nM. IL-8, under identical experimental 
conditions,  did not trigger basophil degranulation  up to a 
100-nM concentration, and induced only negligible histamine 
release at 1/zM. Previously, we reported that IL-3, I1.-5, and 
GM-CSF strongly enhance basophil mediator release in re- 
sponse  to  diverse  agonists  (9,  10).  Consistent  with  these 
studies,  IL-3  also enhanced  the basophil responsiveness to- 
wards MCP-1  (Fig.  1 B).  As reported earlier (11),  IL-8 in- 
duced histamine release in IL-3-primed cells.  However, the 
amount  of histamine release induced by MCP-1 was much 
larger and occurred at lower agonist  concentrations  (EDs0 
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Figure 2.  Comparison  of MCP-1 with  other basophil agonists. Ex- 
perimental conditions  are as described  in Fig. 1. Basophils  were preincubated 
with (filled bars) or without (open bars) rhll~3 (10 ng/ml), and then stimu- 
lated with rhlL-8 (100 nM), rhMCP-1 (30 nM), human C3a (100 riM), 
human C5a (10 riM), or anti-lgE receptor mAb ("aFcelL" 100 ng/ml). 
The mean -+  SEM of histamine (left) and LTC4 (right) release from six 
experiments, each performed  in duplicates  with cells from different  donors, 
is shown. 
"~3  riM)  when  compared with  II.-8  (Fig.  1 B).  In  the ab- 
sence of hematopoietic growth factors, neither MCP-1 nor 
I1.-8 promoted the generation of detectable amounts of LTC4 
(not shown). In the presence of ILo3, however, both agonists 
induced lipid mediator release (Fig.  1 C).  As for histamine 
release, MCP-1 was a much more potent basophil trigger than 
IL-8, and induced the formation of large amounts of LTC4 
concentration dependently over a range of 1-30 nM.  These 
results demonstrate that basophils are stimulated for medi- 
ator release within a similar MCP-1 concentration range as 
previously shown  to activate monocytes (5,  16). 
In Fig.  2,  the effect of MCP-1  was compared with that 
of other basophil agonists  such as I1.-8, the anaphylatoxins 
C3a  and CSa,  and  anti-IgE  receptor antibody (anti-FceR) 
at near optimal concentrations. The data confirm the results 
shown in Fig. 1, and demonstrate a qualitatively similar effect 
of C5a and MCP-1 on basophils. Both agonists triggered hista- 
mine release by themselves, but induced LTC4 production 
only in the presence of II.,3. By contrast, 1I.,8 and C3a were 
able to induce mediator release only after pretreatment with 
II.-3 (11,  14). Identical results were obtained when I1.-3 was 
replaced by II.-5  or GM-CSF  (not shown).  The data show 
that MCP-1, at a 30-nM concentration, is a potent basophil 
agonist,  in particular in the presence of IL-3, inducing  the 
release of comparable amounts of mediators as optimal IgE 
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Figure  1.  Histamine and  LTC4 release by  human 
basophils stimulated with  different concentrations of 
MCP-1 or IL-8. After warming up for 10 min, cells were 
preincubated in buffer (A) or in the presence  of 10 ng/ml 
rhlb3 (/3 and C) for 10 min and then stimulated for 20 
min with different  concentrations  of rhMCP-1 (flied circles) 
or rhlL-8 (open circles). Mediator release  is expressed  as per- 
cent of total cellular histamine content (histamine; A and 
B), and as LTC4 (pg/ng total histamine) (leukotrienes; 
C). The means of duplicates from six experiments per- 
formed with cell preparations from different donors are 
shown. Ib3 by itself did not induce mediator release  (not 
shown). 
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Figure 3.  Changes  in [Ca 2 + ]i in response to MCP-1 and Ib8. Basophils 
(91% purity;  7% neutrophils, 2% lymphocytes), monocytes (90% pu- 
rity; 10% lymphocytes),  and neutrophils (>99% purity) were isolated from 
the same  leukocyte  preparation. Cells were loaded with fura-2/AM, washed, 
and resuspended at a cell density of 0.5  x  106/ml (basophils) or 2.0  x 
106/ml (monocytes, neutrophils). Fluorescence of the call suspensions was 
expressed as percent fura-2 saturation. Arrows indicate the time of MCP-1 
(30 nM) or Ib8 (30 nM) addition. Similar results were obtained from three 
other basophil preparations of 80-90% purity and variable  degrees ofmono- 
cyte (0-3%), lymphocyte (2-12%),  and neutrophil (1-16%) contamina- 
tion. Anti-FceK mAb (500 ng/ml) induced a [Ca  2+ ]i rise of similar mag- 
nitude as MCP-1 in all basophil preparations examined,  but not in monocytes 
or neutrophils (not shown). Lymphocytes  depleted of monocytes,  basophils, 
and neutrophils did not react with [Ca2+]i changes towards MCP-1, Ib8, 
or anti-Fc~R (not  shown). 
taining basophils were used for experiments shown in Figs. 
I  and 2, an indirect effect of MCP-1 through monocytes had 
to be considered. However, the MCP-1 results of Fig. 2 were 
reproducible  with  highly  purified  basophil  preparations 
(80-90%) depleted of monocytes (not shown). The fact that 
MCP-1 is the only yet identified cytokine capable of consis- 
tently inducing basophil histamine release by itself suggests 
a pivotal role of this cytokine in inflammatory reactions in- 
volving basophils. Since basophils are found at the site of al- 
lergic late-phase reactions, which largely determine the severity 
of allergic disease such as asthma (8), MCP-1 should be con- 
sidered as an important mediator of chronic allergic inflam- 
mation. 
The kinetic  of the MCP-l-induced  histamine  and  LTC4 
release was found to be rapid and identical to that previously 
reported for CSa (10), further indicating the similarity of ac- 
tion  between  these  two  agonists  (not  shown).  Leukocyte 
chemotactic  factors  acting  through  G  protein-coupled 
receptors (i.e., C5a and I1.-8) are known to induce a transient 
rise in [Ca  2+ ]i in neutrophils as an early event in signal trans- 
duction (17,  18). Therefore, we loaded highly purified basophil 
preparations with fura-2, and monitored fluorescence changes 
in response to MCP-1 and IL-8, respectively (15). Fig. 3 demon- 
strates that both MCP-1  and IL-8 promote rapid changes in 
intracellular  calcium  concentration  ([Ca2+]i)  in  human 
basophils. A  [CF + ]i change of identical magnitude was ob- 
tained  with  the  specific  basophil  agonist  anti-FceK  (not 
shown).  Interestingly,  the  [Ca2+]i  changes  in  response  to 
MCP-1  or  IL8  were  similar,  indicating  that  the  distinct 
Table  1.  Effect  of PT on Basophil Mediator Release Induced by MCP-I  and Other Agonists 
Percent inhibition  of mediator release* 
Mediator release 
(control)*  PT-B (5  riM)  PT (1  nM)  PT (5  nM)S 
Histamine  Percent release 
MCP-1  11  +  1  -4  _+  6  84  +  14  93  +  12 
IL-3  +  MCP-1  32  -+  5  -8  +  9  27  _+  16  79  +  9 
C5a  23  _+  12  -12  +  5  58  _+  17  90_+  9 
IL-3  +  C5a  43  +  19  4  _+  4  57  _+  34  82  _+  17 
Anti-FceR Ab  29  _+  17  22  _+  9  15  +  8  32  -+ 27 
LTC4  pg/ng  histamine 
IL-3  +  MCP-1  9  _+  1  3  -+  14  73  +  17  90  _+  7 
IL-3  +  C5a  13  _+  3  -4  _+  8  51  _+  35  84  _+  18 
Anti-FceR  Ab  13  _+  6  19  _+  10  15  _+  5  30  _+  24 
* The toxin effects are expressed as percent inhibition of mediator release according to the formula: 100 x  [1 - (release with toxin/release without 
toxin)]  Mean  _+ SD of three different experiments performed in duplicates are shown. 
t Control values are expressed as percent specific release of total cellular histamine content,  or as picograms leukotriene C4 released per nanogram 
total cellular histamine. 
$ PBMC containing basophils were preincubated at 37~  for 90 min without (control) or with 5 nM of the B subunit of Pertussis toxin (PT-B), 
or with 1 and 5 nM PT, respectively, before stimulating the cells as described in Fig. 2. PT and its B subunit did not induce significant mediator 
release by themselves at 1-5 nM (not  shown). 
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differences in signaling events other than calcium mobiliza- 
tion. For comparison,  [Ca2+]i changes in response to MCP-1 
or I1.8 are also shown for monocytes and neutrophils purified 
from the same leukocyte preparation.  Consistent with pub- 
lished data (16), MCP-1 did not influence [Ca  2+ ]i in neutro- 
phils, in contrast to its prominent effect in monocytes. PBL 
depleted of monocytes and basophils responded to neither 
MCP-1 nor to I1.8 (not shown). Collectively, these experi- 
ments strongly suggest that MCP-1 activates basophils directly 
through specific high affinity receptors (19). This condusion 
is further supported by cross-desensitization experiments in 
purified basophils demonstrating  that the cells were deacti- 
vated  towards  a  second challenge  with  the  same  agonist 
(MCP-1  or I1.8,  respectively; not  shown),  but not  if one 
cytokine was followed by the other (Fig. 3). Similarly, I1.8 
preincubation did not inhibit the MCP-l-induced mediator 
release (not shown), in contrast to its inhibitory activity to- 
wards  I1.8 stimulation  (20). 
Since the receptors for CSa, FMLP, and I1.8 are all cou- 
pled  to  PT-sensitive  G-protein(s)  (17,  18),  we  examined 
whether MCP-loinduced basophil activation is inhibited by 
PT. As a control for G protein-independent toxin effects, the 
B  subunit  of PT was included in these experiments.  Table 
I illustrates that PT, but not its B subunit, strongly inhibited 
MCP-l-induced mediator release.  As expected, the C5a re- 
sponse was similarly reduced, in contrast to the IgE-dependent 
stimulation  (21).  Furthermore,  the [Ca  2+ ]i change induced 
by MCP-1  or C5a was inhibited  by >90%  by 5  nM PT, 
whereas the calcium signal induced by anti-FceR was un- 
changed  (not  shown).  Thus,  MCP-1  appears  to  induce 
[Ca2+]i  changes  in  a  similar  way  as  other  chemotactic 
agonists,  presumably by interacting  with a specific  G pro- 
tein-coupled receptor. 
MCP-1 represents the first identified cytokine capable of 
directly inducing  mediator  release  by human basophils,  in 
preliminary  experiments,  we found no histamine release in 
response to RANTES, MIP-lcz, or MIP-lfl, indicating that 
the potent basophil-activating  property of MCP-1  may be 
unique,  even  among  the  members  of the  P,  ANTES/SIS 
cytokine family. Basophils, as target cells of MCP-1 action, 
may thus be involved in processes (3, 22, 23) in which MCP-1 
is upregulated. This implies the interesting possibility of an 
additional  role of basophils  outside allergic disease. 
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